According to National Cancer Institute's SEER database, the average five-year survival rate of HCC patients in the US is 19.6% but can be as low as 2.5% for advanced, metastatic disease. When diagnosed at early stages, it is treatable with locoregional treatments including surgical resection,...
Genotype C is related to liver cirrhosis an d cancer. T he cumulative survival rate of gen otype B is significantly higher than genotype C. Recent studies showed that, the mutation r ate of HBV is about 10 times higher than ot her DNA. HBV variation is related to cdinical outcome.T ...
国外有多种分期方案,如:BCLC、TNM、JSH 和 APASL 等。结 合中国的具体国情及实践积累,依据患者体力活动状态 (Performance status,PS)、肝肿瘤及肝功能情况,建立中国肝癌的分期方案(China liver cancer staging, CNLC), 包括:CNLC Ⅰa ...
11,12 After resection, recurrence within the residual cirrhotic liver is high, with more than 50% of patients developing HCC recurrence within 3 years and 70–80% recurring within 5 years; the 5-year survival rate for these patients is approximately 40–50%.[13], [14], [15], [16], ...
SOR是第一个被证明对晚期HCC临床治疗有效小分子TKI类靶向药[6],根据SHARP研究,与安慰剂组相比,SOR延长患者中位总生存(median overall survival,mOS)时间2.8个月[6],但在随后的ORIENTAL研究中,SOR仅延长患者mOS时间1.3个月。其原因可能与...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is the fastest growing cause of cancer death in the United States (U.S.), estimated to be responsible for approximately 30,000 deaths annually [1,2]. HCC is the most common primary malignant liver tu...
Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by poor prognosis and a low 5-year survival rate. Drug treatment is proving to be effective in anti-HCC. However, only a small number of HCC patients exhibit sensitive responses,
阐明当前可用的靶向药物在高龄患者中的安全性和有效性就显得至关重要。 日本学者Masatoshi Kudo发表于Liver Cancer的一篇文章,对HCC全身系统治疗的最新进展及全身系统治疗在老年患者中的有效性和安全性展开阐述。肝胆相照平台特将其中靶向药物章节摘译并发表,以期为临床高龄患者靶向治疗提供参考。
With a high and durable disease control rate of 61% at 18 weeks, the majority of patients in this study have continuous clinical benefit. - "Hepatocellular cancer is a particularly complex disease," says Dr Maria Reig, Director of ...
The overall survival rate appeared to be very promising. It was 10.6 months in patients who have tried sorafenib and couldn’t tolerate it or who broke through. And it was very appealing regarding the progression-free survival as well. It was approximately 5.5 months. In the control group, ...